Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Anacor Pharmaceuticals Inc (ANAC) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Anacor Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1411158.
Total stock buying since 2014: $301,114.
Total stock sales since 2014: $239,839,203.
Total stock option exercises since 2014: $4,965,245.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2016 | 0 | $0 | 668,145 | $58,464,338 | 129,800 | $1,296,052 |
| 2015 | 3,000 | $157,305 | 1,405,907 | $144,337,450 | 209,002 | $2,003,878 |
| 2014 | 6,590 | $143,809 | 1,334,785 | $37,037,415 | 245,723 | $1,665,315 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2016-06 | 0 | $0 | 751 | $74,559 | 0 | $0 |
| 2016-05 | 0 | $0 | 362,881 | $36,160,480 | 9,000 | $127,980 |
| 2016-04 | 0 | $0 | 232,426 | $16,895,587 | 0 | $0 |
| 2016-03 | 0 | $0 | 46,500 | $2,829,976 | 89,000 | $679,782 |
| 2016-01 | 0 | $0 | 25,587 | $2,503,736 | 31,800 | $488,290 |
| 2015-12 | 0 | $0 | 1,004,000 | $112,013,406 | 64,000 | $894,560 |
| 2015-11 | 0 | $0 | 100,295 | $10,390,562 | 0 | $0 |
| 2015-09 | 0 | $0 | 34,000 | $4,754,538 | 34,000 | $181,360 |
| 2015-08 | 0 | $0 | 20,000 | $2,759,300 | 20,000 | $102,200 |
| 2015-06 | 0 | $0 | 12,600 | $871,113 | 12,000 | $75,060 |
| 2015-05 | 0 | $0 | 77,522 | $4,857,904 | 62,002 | $630,658 |
| 2015-04 | 0 | $0 | 62,645 | $3,942,230 | 0 | $0 |
| 2015-03 | 3,000 | $157,305 | 79,895 | $4,229,377 | 17,000 | $120,040 |
| 2015-02 | 0 | $0 | 7,475 | $279,228 | 0 | $0 |
| 2015-01 | 0 | $0 | 7,475 | $239,792 | 0 | $0 |
| 2014-12 | 0 | $0 | 387,060 | $13,559,662 | 187,285 | $1,290,955 |
| 2014-11 | 0 | $0 | 12,475 | $394,018 | 5,000 | $36,250 |
| 2014-10 | 0 | $0 | 7,475 | $182,542 | 0 | $0 |
| 2014-09 | 6,590 | $143,809 | 900,754 | $22,345,646 | 42,185 | $258,383 |
| 2014-08 | 0 | $0 | 23,901 | $510,520 | 11,253 | $79,727 |
| 2014-06 | 0 | $0 | 1,620 | $23,796 | 0 | $0 |
| 2014-05 | 0 | $0 | 1,500 | $21,231 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2016-06-01 | Bell Graeme (Executive VP and CFO) | Sale | 751 | 99.28 | 74,559 |
| 2016-05-23 | Leonard Keith R (Director) | Sale | 9,000 | 99.70 | 897,300 |
| 2016-05-23 | Leonard Keith R (Director) | Option Ex | 9,000 | 14.22 | 127,980 |
| 2016-05-16 | Hove Anders D (Director) | Sale | 353,881 | 99.65 | 35,263,180 |
| 2016-04-29 | Sullivan Ryan T (EVP and General Counsel) | Sale | 3,125 | 66.33 | 207,281 |
| 2016-04-08 | Hove Anders D (Director) | Sale | 4,268 | 70.72 | 301,854 |
| 2016-04-07 | Hove Anders D (Director) | Sale | 225,033 | 72.82 | 16,386,452 |
| 2016-03-31 | Rieflin William Jl (Director) | Option Ex | 89,000 | 7.64 | 679,782 |
| 2016-03-22 | Berns Paul L (President and CEO) | Sale | 37,500 | 60.17 | 2,256,487 |
| 2016-03-02 | Ippolito Vincent P (EVP & Chief Commercial Officer) | Sale | 9,000 | 63.72 | 573,489 |
| 2016-01-22 | Zane Lee (SVP and Chief Medical Officer) | Option Ex | 11,800 | 7.55 | 89,090 |
| 2016-01-19 | Ippolito Vincent P (EVP & Chief Commercial Officer) | Sale | 20,000 | 95.54 | 1,910,780 |
| 2016-01-19 | Ippolito Vincent P (EVP & Chief Commercial Officer) | Option Ex | 20,000 | 19.96 | 399,200 |
| 2016-01-15 | Zane Lee (SVP and Chief Medical Officer) | Sale | 1,466 | 89.57 | 131,309 |
| 2016-01-04 | Sullivan Ryan T (Sr. VP and General Counsel) | Sale | 733 | 111.72 | 81,892 |
| 2016-01-04 | Ippolito Vincent P (EVP & Chief Commercial Officer) | Sale | 855 | 112.07 | 95,819 |
| 2016-01-04 | Berns Paul L (President and CEO) | Sale | 2,533 | 112.09 | 283,936 |
| 2015-12-15 | Zane Lee (SVP and Chief Medical Officer) | Sale | 14,000 | 113.49 | 1,588,916 |
| 2015-12-15 | Zane Lee (SVP and Chief Medical Officer) | Option Ex | 14,000 | 5.59 | 78,260 |
| 2015-12-15 | Hove Anders D (Director) | Sale | 900,000 | 111.25 | 100,125,000 |
| 2015-12-11 | Hove Anders D (Director) | Sale | 40,000 | 117.36 | 4,694,400 |
| 2015-12-11 | Berns Paul L (President and CEO) | Sale | 20,000 | 117.19 | 2,343,760 |
| 2015-12-11 | Berns Paul L (President and CEO) | Option Ex | 20,000 | 13.21 | 264,100 |
| 2015-12-10 | Sullivan Ryan T (Sr. VP and General Counsel) | Sale | 10,000 | 110.06 | 1,100,590 |
| 2015-12-10 | Sullivan Ryan T (Sr. VP and General Counsel) | Option Ex | 10,000 | 15.30 | 153,000 |
| 2015-12-09 | Ippolito Vincent P (EVP & Chief Commercial Officer) | Sale | 20,000 | 108.04 | 2,160,740 |
| 2015-12-09 | Ippolito Vincent P (EVP & Chief Commercial Officer) | Option Ex | 20,000 | 19.96 | 399,200 |
| 2015-11-10 | Hove Anders D (Director) | Sale | 100,295 | 103.60 | 10,390,562 |
| 2015-09-15 | Zane Lee (SVP and Chief Medical Officer) | Sale | 14,000 | 139.85 | 1,957,858 |
| 2015-09-15 | Zane Lee (SVP and Chief Medical Officer) | Option Ex | 14,000 | 5.59 | 78,260 |
| 2015-09-15 | Berns Paul L (President and CEO) | Sale | 20,000 | 139.83 | 2,796,680 |
| 2015-09-15 | Berns Paul L (President and CEO) | Option Ex | 20,000 | 5.16 | 103,100 |
| 2015-08-13 | Berns Paul L (President and CEO) | Sale | 20,000 | 137.97 | 2,759,300 |
| 2015-08-13 | Berns Paul L (President and CEO) | Option Ex | 20,000 | 5.11 | 102,200 |
| 2015-06-15 | Zane Lee (SVP and Chief Medical Officer) | Sale | 12,000 | 69.05 | 828,588 |
| 2015-06-15 | Zane Lee (SVP and Chief Medical Officer) | Option Ex | 12,000 | 6.25 | 75,060 |
| 2015-06-01 | Maples Kirk R (SVP, Program Management) | Sale | 600 | 70.88 | 42,525 |
| 2015-05-15 | Plattner Jacob J (Senior VP, Research) | Sale | 8,920 | 63.73 | 568,471 |
| 2015-05-14 | Rodriguez Carmen R (Snr VP Reg Afrs & Qual. Assur.) | Sale | 6,000 | 63.76 | 382,554 |
| 2015-05-13 | Rodriguez Carmen R (Snr VP Reg Afrs & Qual. Assur.) | Sale | 41,768 | 62.83 | 2,624,116 |
| 2015-05-13 | Rodriguez Carmen R (Snr VP Reg Afrs & Qual. Assur.) | Option Ex | 41,768 | 11.74 | 490,356 |
| 2015-05-12 | Rodriguez Carmen R (Snr VP Reg Afrs & Qual. Assur.) | Sale | 14,174 | 62.05 | 879,553 |
| 2015-05-12 | Rodriguez Carmen R (Snr VP Reg Afrs & Qual. Assur.) | Option Ex | 14,174 | 6.94 | 98,367 |
| 2015-05-12 | Maples Kirk R (SVP, Program Management) | Sale | 6,060 | 61.23 | 371,071 |
| 2015-05-12 | Maples Kirk R (SVP, Program Management) | Option Ex | 6,060 | 6.92 | 41,935 |
| 2015-05-01 | Maples Kirk R (SVP, Program Management) | Sale | 600 | 53.57 | 32,139 |
| 2015-04-29 | Sullivan Ryan T (Sr. VP and General Counsel) | Sale | 3,125 | 53.61 | 167,531 |
| 2015-04-27 | Berns Paul L (President and CEO) | Sale | 25,000 | 61.71 | 1,542,650 |
| 2015-04-24 | Berns Paul L (President and CEO) | Sale | 25,000 | 65.50 | 1,637,575 |
| 2015-04-15 | Plattner Jacob J (Senior VP, Research) | Sale | 8,920 | 62.81 | 560,265 |
| 2015-04-01 | Maples Kirk R (SVP, Program Management) | Sale | 600 | 57.02 | 34,209 |
| 2015-03-23 | Parker Geoffrey M. (Executive Vice President & CFO) | Buy | 3,000 | 52.44 | 157,305 |
| 2015-03-19 | Berns Paul L (President and CEO) | Sale | 37,500 | 56.07 | 2,102,662 |
| 2015-03-16 | Zane Lee (SVP and Chief Medical Officer) | Sale | 12,000 | 56.51 | 678,156 |
| 2015-03-16 | Zane Lee (SVP and Chief Medical Officer) | Option Ex | 12,000 | 6.92 | 83,040 |
| 2015-03-16 | Plattner Jacob J (Senior VP, Research) | Sale | 8,920 | 55.60 | 495,952 |
| 2015-03-04 | Chanda Sanjay (SVP, Drug Development) | Sale | 5,000 | 45.00 | 225,000 |
| 2015-03-04 | Chanda Sanjay (SVP, Drug Development) | Option Ex | 5,000 | 7.40 | 37,000 |
| 2015-03-03 | Ippolito Vincent P (EVP & Chief Commercial Officer) | Sale | 9,000 | 44.08 | 396,711 |
| 2015-03-02 | Maples Kirk R (SVP, Program Management) | Sale | 600 | 43.95 | 26,368 |
| 2015-03-02 | Plattner Jacob J (Senior VP, Research) | Sale | 6,875 | 44.30 | 304,528 |
| 2015-02-02 | Maples Kirk R (SVP, Program Management) | Sale | 600 | 37.41 | 22,447 |
| 2015-02-02 | Plattner Jacob J (Senior VP, Research) | Sale | 6,875 | 37.35 | 256,781 |
| 2015-01-02 | Maples Kirk R (SVP, Program Management) | Sale | 600 | 31.96 | 19,174 |
| 2015-01-02 | Plattner Jacob J (Senior VP, Research) | Sale | 6,875 | 32.09 | 220,618 |
| 2014-12-29 | Zane Lee (SVP and Chief Medical Officer) | Option Ex | 14,291 | 6.50 | 92,891 |
| 2014-12-26 | Berns Paul L (President and CEO) | Sale | 25,000 | 30.82 | 770,500 |
| 2014-12-19 | Chanda Sanjay (SVP, Drug Development) | Option Ex | 19,073 | 6.25 | 119,301 |
| 2014-12-12 | Shapiro Lucy (Director) | Sale | 49,831 | 34.46 | 1,717,325 |
| 2014-12-11 | Zane Lee (SVP and Chief Medical Officer) | Sale | 100 | 36.00 | 3,600 |
| 2014-12-11 | Zane Lee (SVP and Chief Medical Officer) | Option Ex | 100 | 5.00 | 500 |
| 2014-12-11 | Shapiro Lucy (Director) | Sale | 150,833 | 34.91 | 5,266,334 |
| 2014-12-10 | Zane Lee (SVP and Chief Medical Officer) | Sale | 4,800 | 36.09 | 173,251 |
| 2014-12-10 | Zane Lee (SVP and Chief Medical Officer) | Option Ex | 4,800 | 5.00 | 24,000 |
| 2014-12-10 | Shapiro Lucy (Director) | Sale | 89,021 | 35.79 | 3,185,705 |
| 2014-12-10 | Shapiro Lucy (Director) | Option Ex | 89,021 | 7.63 | 678,963 |
| 2014-12-09 | Maples Kirk R (SVP, Program Management) | Sale | 60,000 | 36.52 | 2,191,380 |
| 2014-12-09 | Maples Kirk R (SVP, Program Management) | Option Ex | 60,000 | 6.25 | 375,300 |
| 2014-12-01 | Maples Kirk R (SVP, Program Management) | Sale | 600 | 33.64 | 20,182 |
| 2014-12-01 | Plattner Jacob J (Senior VP, Research) | Sale | 6,875 | 33.66 | 231,385 |
| 2014-11-26 | Chanda Sanjay (SVP, Drug Development) | Sale | 5,000 | 35.00 | 175,000 |
| 2014-11-26 | Chanda Sanjay (SVP, Drug Development) | Option Ex | 5,000 | 7.25 | 36,250 |
| 2014-11-03 | Maples Kirk R (SVP, Program Management) | Sale | 600 | 29.09 | 17,457 |
| 2014-11-03 | Plattner Jacob J (Senior VP, Research) | Sale | 6,875 | 29.32 | 201,561 |
| 2014-10-01 | Maples Kirk R (SVP, Program Management) | Sale | 600 | 23.85 | 14,311 |
| 2014-10-01 | Plattner Jacob J (Senior VP, Research) | Sale | 6,875 | 24.47 | 168,231 |
| 2014-09-26 | Hove Anders D (Director) | Sale | 20,000 | 25.00 | 500,000 |
| 2014-09-19 | Hove Anders D (Director) | Sale | 738,500 | 24.87 | 18,366,495 |
| 2014-09-18 | Hove Anders D (Director) | Sale | 1,500 | 24.87 | 37,305 |
| 2014-09-16 | Hove Anders D (Director) | Sale | 75,000 | 24.99 | 1,874,249 |
| 2014-09-12 | Hove Anders D (Director) | Sale | 15,000 | 24.98 | 374,700 |
| 2014-09-10 | Chanda Sanjay (SVP, Drug Development) | Sale | 10,000 | 24.25 | 242,500 |
| 2014-09-10 | Chanda Sanjay (SVP, Drug Development) | Option Ex | 10,000 | 6.12 | 61,250 |
| 2014-09-08 | Parker Geoffrey M. (Executive Vice President & CFO) | Buy | 1,229 | 22.05 | 27,095 |
| 2014-09-05 | Parker Geoffrey M. (Executive Vice President & CFO) | Buy | 5,361 | 21.77 | 116,714 |
| 2014-09-02 | Maples Kirk R (SVP, Program Management) | Sale | 33,879 | 23.32 | 789,956 |
| 2014-09-02 | Maples Kirk R (SVP, Program Management) | Option Ex | 32,185 | 6.12 | 197,133 |
| 2014-09-02 | Plattner Jacob J (Senior VP, Research) | Sale | 6,875 | 23.34 | 160,441 |
| 2014-08-27 | Leschly Mark (Director) | Sale | 13,067 | 22.50 | 294,007 |
| 2014-08-13 | Maples Kirk R (SVP, Program Management) | Sale | 3,959 | 19.96 | 79,013 |
| 2014-08-13 | Maples Kirk R (SVP, Program Management) | Option Ex | 11,253 | 7.08 | 79,727 |
| 2014-08-13 | Plattner Jacob J (Senior VP, Research) | Sale | 6,875 | 20.00 | 137,500 |
| 2014-06-04 | Maples Kirk R (SVP, Program Management) | Sale | 1,620 | 14.69 | 23,796 |
| 2014-05-20 | Maples Kirk R (SVP, Program Management) | Sale | 1,500 | 14.15 | 21,231 |
Insider trading activities including stock purchases, stock sales, and option exercises of ANAC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Anacor Pharmaceuticals Inc (symbol ANAC, CIK number 1411158) see the Securities and Exchange Commission (SEC) website.